Drug Profile
KA 2237
Alternative Names: CVL-237; KA2237; PI3 Kinase p110β/δ inhibitorLatest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Karus Therapeutics
- Developer Karus Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
- Preclinical Inflammation
Most Recent Events
- 05 Mar 2024 Convalife plans a phase II/III trial for Immunodeficiency disorders in China (PO, Tablet) in March 2024 (NCT06293716)
- 25 Dec 2023 Convalife plans a phase II trial for Solid tumours (Late-stage disease) in China (NCT06183736)
- 29 Mar 2023 KA 2237 is still in phase I development for B-cell lyphoma in the US